The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The Neurotoxicant, Cuprizone, as a Model to Study Demyelination and Remyelination in the Central Nervous System
Open accessAbstract
Myelin of the adult CNS is vulnerable to a variety of metabolic, toxic, and autoimmune insults. That remyelination can ensue, following demyelinating insult, has been well demonstrated. Details of the process of remyelination are, however difficult to ascertain since in most experimental models of demyelination/remyelination the severity, localization of lesion site, or time course of the pathophysiology is variable from animal to animal. In contrast, an experimental model in which massive demyelination can be reproducibly induced in large areas of mouse brain is exposure to the copper chelator, cuprizone, in the diet. We review work from several laboratories over the past 3 decades, with emphasis on our own recent studies, which suggest an overall picture of cellular events involved in demyelination/remyelination. When 8 week old C57BL/6 mice are fed 0.2% cuprizone in the diet, mature olidgodendroglia are specifically insulted (cannot fulfill the metabolic demand of support of vast amounts of myelin) and go through apoptosis.This is closely followed by recruitment of microglia and phagoctytosis of myelin. Studies of myelin gene expression, coordinated with morphological studies, indicate that even in the face of continued metabolic challenge, oligodendroglial progenitor cells proliferate and invade demyelinated areas. If the cuprizone challenge is terminated, an almost complete remyelination takes place in a matter of weeks. Communication between different cell types by soluble factors may be inferred. This material is presented in the context of a model compatible with present data—and which can be tested more rigorously with the cuprizone model. The reproducibility of the model indicates that it may allow for testing of manipulations (e.g. available knockouts or transgenics on the common genetic background, or pharmacological treatments) which may accelerate or repress the process of demyelination and or remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The C57BL/6 mice showed a dramatic loss of myelin staining at this time point (Fig. 1b), which is consistent with previous reports [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon treatment with cuprizone, mice typically exhibit profound demyelination in the corpus callosum, the cortex and the superior cerebellar peduncles [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most investigators use the standard C57BL/6 mouse strain in the cuprizone model to study the different molecular components involved in the complex pathogenic processes leading to corpus callosum demyelination [5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the corpus callosum, apoptosis of oligodendrocytes is observed, together with recruitment of microglia/macrophages, astrocytes and oligodendrocyte progenitor cells (OPCs) [5, 6].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the continuous exposure of C57BL/6 mice to cuprizone results in a pattern of two cycles of demyelination and remyelination, followed by chronic demyelination from which animals do not recover 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, C57BL/6 mice experience a spontaneous partial remyelination after 6 weeks and then continue to demyelinate further when exposed continuously to cuprizone 36, 39.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, unlike microglia and astrocytes in C57BL/6 mice that respond vigorously to demyelination 2, 23, 39, these cell types in SJL mice have a guarded response at midline and in the lateral region, which correlates with subdued demyelination.”
From SJL Mice Exposed to Cuprizone Intoxication Reveal Strain and Gender Pattern Differences in Demyelination (2009) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cuprizone toxicity produces profound demyelination in the white and grey matter of the brain that mirrors sites of MS pathology [46].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other features common to both cuprizone-induced and type 3 MS lesions are mitochondrial stress, selective loss of myelin-associated glycoprotein (MAG), lesions with indistinct borders that are not perivascular, pronounced glial activation, and lymphocyte infiltration [43, 46, 65, 69–71].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The histopathological hallmark of the cuprizone model as standardized by Hiremath is oligodendrocyte death and subsequent demyelination in the corpus callosum, superior cerebellar peduncles, hippocampus [42, 46–54] and several other areas of the mouse brain (reviewed in [20]).”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial activation and axonal loss positively correlate with demyelination and the reproducible lesion localization – primarily in the corpus callosum [186], cerebellar peduncle [186], hippocampus [187], and cortex [184, 185, 188] – mirrors the topographical specificity of MS pathology, including subpial cortical demyelination seen in PMS patients.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remyelination is very robust in the cuprizone model and starts directly after demyelination is complete, irrespective if cuprizone is further fed or not (Matsushima and Morell, 2001; Hiremath et al., 2008; Gudi et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depletion of microglia likewise prevented the loss of oligodendrocytes (OLs) in the CC that normally results from CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The cuprizone model involves administration of the toxin cuprizone to induce oligodendrocyte apoptosis [4, 5].”
From Strain differences in cuprizone induced demyelination (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Here, we explored the effect of antibody-mediated TREM2 activation on microglia in a well-established toxin-induced model of demyelination in the CNS resulting from exposure to the copper chelator cuprizone (CPZ) in the diet [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“These events lead to OPC recruitment, differentiation into mature OLs, and then remyelination which is almost complete within few weeks from toxin withdrawal [31].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [31]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It may suggest that NODDI could be sensitive biomarkers to probe the different stages of white matter pathology between acute demyelination and chronic demyelination (Matsushima and Morell 2001).”
From Neurite orientation dispersion and density imaging of mouse brain microstructure (2019) · cites this paper as Matsushima and Morell 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Historically these cells are not linked to demyelination following cuprizone treatment because the loss of the V(D)J recombination activation gene-1 (RAG-1), which is critical for B- and T- lymphocyte generation [269], does not alter demyelination and T-cell accumulation in the corpus callosum [46, 270].”
From Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination (2022) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Demyelination peaks between 4.5 and 5 weeks of cuprizone exposure in the CC and between 5 and 6 weeks in the cortex and hippocampus (Hiremath et al., 1998; Matsushima and Morell, 2001; Skripuletz et al., 2008; Gudi et al., 2009; Koutsoudaki et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Strong astrogliosis comprising hypertrophy and hyperplasia of astrocytes occurs as a response to cuprizone treatment in different white and gray matter structures for instance the CC (Matsushima and Morell, 2001; Gudi et al., 2009), hippocampus, (Koutsoudaki et al., 2009; Norkute et al., 2009), cerebellum, cortex (Skripuletz et al., 2008), and basal ganglia (Pott et al., 2009).”
From Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned (2014) · cites this paper as Matsushima and Morell, 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Astrogliosis is an additional pathological hallmark of CUP treatment (Matsushima & Morell, 2001).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Matsushima & Morell, 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice
Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 412
Self-citation(1978) · PubMed · Cited by 297
Nishiyama, A., Lin, X., Giese, N. A., Heldin, C., & Stallcup, W. B. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960201)43:3 · Cited by 244
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Self-citationKomoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Blakemore, W. F. (1972) · Journal of Neurocytology · doi:10.1007/bf01102943 · Cited by 217
Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination
Morell, P., Barrett, C. V., Mason, J. L., Toews, A. D., Hostettler, J. D., Knapp, G. W., & Matsushima, G. K. (1998) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1998.0715 · Cited by 213
Self-citationDemyelination of the superior cerebellar peduncle in the mouse induced by cuprizone
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90118-4 · Cited by 207
Blakemore, W. F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90119-6 · Cited by 177
Research works printed but not linked: 2
- Jurevics HA, 2000, Lipid metabolism during remyelination in brain, J Neurochem, 74, S32
- Ludwin SK, 1980, Chronic demyelination inhibits remyelination in the central nervous system, Lab Invest, 43, 382
Cited by
Sorted by citations
Items 301–400 of 985
Doucette, J. R., Jiao, R., & Nazarali, A. J. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9486-z · Cited by 53
TAM Receptor Signalling and Demyelination
Binder, M. D., & Kilpatrick, T. J. (2009) · Neurosignals · doi:10.1159/000231894 · Cited by 51
Li, J., Ghiani, C. A., Kim, J. Y., Liu, A., Sandoval, J., deVellis, J., & Casaccia‐Bonnefil, P. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0184-08.2008 · Cited by 53
Liu, S., Ren, C., Qu, X., Wu, X., Dong, F., Chand, Y. K., Fan, H., Yao, R., & Geng, D. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13485 · Cited by 52
Restoration of FcRγ/Fyn signaling repairs central nervous system demyelination
Seiwa, C., Yamamoto, M., Tanaka, K., Fukutake, M., Ueki, T., Takeda, S., Sakai, R., Ishige, A., Watanabe, K., Akita, M., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21196 · Cited by 50
Plant, S. R., Iocca, H. A., Wang, Y., Thrash, J. C., O'Connor, B. P., Arnett, H. A., Fu, Y.-X., Carson, M. J., & Ting, J. P.-Y. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1307-07.2007 · Cited by 51
Vakilzadeh, G., Khodagholi, F., Ghadiri, T., Ghaemi, A., Noorbakhsh, F., Sharifzadeh, M. S., & Gorji, A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9404-y · Cited by 50
Xu, H., Yang, H.-J., Rose, G. M., & Li, X. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00031 · Cited by 49
Grinspan, J. B. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2015.05.005 · Cited by 51
Regulation and dysregulation of axon infrastructure by myelinating glia
Pan, S., & Chan, J. R. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201702150 · Cited by 52
Functional antagonism of sphingosine‐1‐phosphate receptor 1 prevents cuprizone‐induced demyelination
Kim, S.-J., Bielawski, J., Yang, H., Kong, Y., Zhou, B., & Li, J. (2017) · Glia · doi:10.1002/glia.23272 · Cited by 50
Cuprizone feed formulation influences the extent of demyelinating disease pathology
Toomey, L. M., Papini, M. G., Lins, B. R., Wright, A. J., Warnock, A., McGonigle, T. A., Hellewell, S. C., Bartlett, C. A., Anyaegbu, C. C., & Fitzgerald, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-01963-3 · Cited by 50
Nessler, J. N., Bénardais, K., Gudi, V., Hoffmann, A., Tejedor, L. S., Janßen, S., Prajeeth, C. K., Baumgärtner, W., Kavelaars, A., Heijnen, C. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069795 · Cited by 50
Xuan, Y., Yan, G., Wu, R., Huang, Q., Li, X., & Xu, H. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.08.015 · Cited by 50
Zimmermann, J., Emrich, M., Krauthausen, M., Saxe, S., Nitsch, L., Heneka, M. T., Campbell, I. L., & Müller, M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0368-3 · Cited by 52
Bölcskei, K., Kriszta, G., Sághy, É., Payrits, M., Sipos, É., Vranesics, A., Berente, Z., Ábrahám, H., Ács, P., Komoly, S., et al. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.020 · Cited by 51
Wang, Y., Zhang, Y., Zhang, S., Kim, B., Hull, V. L., Xu, J., Prabhu, P., Gregory, M., Martínez‐Cerdeño, V., Zhan, X., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109695 · Cited by 48
Dynamic Responses of Microglia in Animal Models of Multiple Sclerosis
Plastini, M. J., Desu, H. L., & Brambilla, R. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00269 · Cited by 48
Microglial Hv1 proton channels promote white matter injuries after chronic hypoperfusion in mice
Yu, Y., Luo, X., Li, C., Ding, F., Wang, M., Xie, M., Yu, Z., Ransom, B. R., & Wang, W. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14925 · Cited by 47
Lin, Y., Huang, G., Jamison, S., Li, J., Harding, H. P., Ron, D., & Lin, W. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.10.009 · Cited by 49
Wang, H., Liu, S., Tian, Y., Wu, X., He, Y., Li, C., Namaka, M., Kong, J., Li, H., & Xiao, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00492 · Cited by 50
rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination
Mullin, A. P., Cui, C., Wang, Y., Wang, J., Troy, E. L., Caggiano, A. O., Parry, T. J., Colburn, R. W., & Pavlopoulos, E. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.015 · Cited by 48
Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease
Yamamoto, S., Yamashina, K., Ishikawa, M., Gotoh, M., Yagishita, S., Iwasa, K., Maruyama, K., Murakami‐Murofushi, K., & Yoshikawa, K. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0923-5 · Cited by 48
Human IPSC-Derived Model to Study Myelin Disruption
Chesnut, M., Paschoud, H., Repond, C., Smirnova, L., Härtung, T., Zurich, M., Högberg, H. T., & Pamies, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179473 · Cited by 56
Deleterious Role of IFNγ in a Toxic Model of Central Nervous System Demyelination
Maña, P., Liñares, D., Fordham, S., Staykova, M., & Willenborg, D. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050799 · Cited by 48
Hedayatpour, A., Kashani, I. R., Pasbakhsh, P., Kafami, L., Atlasi, N., Mahabadi, V. P., Ghasemi, S., & Reza, M. (2013) · Europe PMC (PubMed Central) · Cited by 46
Loss of HDAC11 ameliorates clinical symptoms in a multiple sclerosis mouse model
Sun, L., Telles, E., Karl, M. T., Cheng, F., Luetteke, N., Sotomayor, E. M., Miller, R. H., & Seto, E. (2018) · Life Science Alliance · doi:10.26508/lsa.201800039 · Cited by 49
Wellman, S. M., Guzman, K., Stieger, K. C., Brink, L. E., Sridhar, S., Dubaniewicz, M. T., Li, L., Cambi, F., & Kozai, T. D. Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119842 · Cited by 44
White matter biomarkers from fast protocols using axially symmetric diffusion kurtosis imaging
Hansen, B., Khan, A. R., Shemesh, N., Lund, T. E., Sangill, R., Eskildsen, S. F., Østergaard, L., & Jespersen, S. N. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3741 · Cited by 46
Zhao, Z., Li, T., Dong, X., Wang, X., Zhang, Z., Zhao, C., Kang, X., Zheng, R., & Li, X. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/7093844 · Cited by 47
Glial aging and its impact on central nervous system myelin regeneration
Rawji, K. S., Neumann, B., & Franklin, R. J. M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14933 · Cited by 47
Palumbo, S., Toscano, C. D., Parente, L., Weigert, R., & Bosetti, F. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07363.x · Cited by 46
Maña, P., Fordham, S. A., Staykova, M. A., Correcha, M., Silva, D., Willenborg, D. O., & Liñares, D. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.013 · Cited by 46
Aparicio, E., Mathieu, P., Luppi, M. P., Gubiani, M. F. A., & Adamo, A. M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12440 · Cited by 47
Yano, R., Hata, J., Abe, Y., Seki, F., Yoshida, K., Komaki, Y., Okano, H., & Tanaka, K. F. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.10.004 · Cited by 46
Zilkha‐Falb, R., Kaushansky, N., Kawakami, N., & Ben‐Nun, A. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0468-4 · Cited by 45
Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination
Houben, E., Janssens, K., Hermans, D., Vandooren, J., den Haute, C. V., Schepers, M., Vanmierlo, T., Lambrichts, I., van Horssen, J., Baekelandt, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912910117 · Cited by 44
N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation
Sy, M., Brandt, A. U., Lee, S.-U., Newton, B. L., Pawling, J., Golzar, A., Rahman, A. M. A., Yu, Z., Cooper, G., Scheel, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015595 · Cited by 44
Herder, V., Hansmann, F., Stangel, M., Skripuletz, T., Baumgärtner, W., & Beineke, A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01168.x · Cited by 45
The conundrum of iron in multiple sclerosis – time for an individualised approach
van Rensburg, S. J., Kotze, M. J., & van Toorn, R. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9290-1 · Cited by 45
Erythropoietin Attenuates Neurological and Histological Consequences of Toxic Demyelination in Mice
Hagemeyer, N., Boretius, S., Ott, C., von Streitberg, A., Welpinghus, H., Sperling, S., Frahm, J., Simons, M., Ghezzi, P., & Ehrenreich, H. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00457 · Cited by 44
The landscape of targets and lead molecules for remyelination
Caprariello, A. V., & Adams, D. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01115-2 · Cited by 46
Faria, D. D. P., de Vries, E. F. J., Sijbesma, J. W. A., Dierckx, R., Buchpiguel, C. A., & Copray, S. C. V. M. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.057 · Cited by 44
Pathology of inflammatory diseases of the nervous system: Human disease versus animal models
Lassmann, H. (2019) · Glia · doi:10.1002/glia.23726 · Cited by 44
Zhang, N., Liu, C., Zhang, R., Jin, L., Yin, X., Zheng, X., Siebert, H., Li, Y., Wang, Z., Loers, G., et al. (2020) · Food & Function · doi:10.1039/c9fo02944c · Cited by 47
Maheshwari, A., Janssens, K., Bogie, J. F. J., den Haute, C. V., Struys, T., Lambrichts, I., Baekelandt, V., Stinissen, P., Hendriks, J. J. A., Slaets, H., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/685317 · Cited by 44
Expression of Translocator Protein and [18F]-GE180 Ligand Uptake in Multiple Sclerosis Animal Models
Nack, A., Brendel, M., Nedelcu, J., Daerr, M., Nyamoya, S., Beyer, C., Focke, C., Deussing, M., Hoornaert, C., Ponsaerts, P., et al. (2019) · Cells · doi:10.3390/cells8020094 · Cited by 43
Hochstrasser, T., Exner, G. L., Nyamoya, S., Schmitz, C., & Kipp, M. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0903-3 · Cited by 43
Astrocyte and oligodendrocyte pathology in Alzheimer's disease
Ziar, R., Tesar, P. J., & Clayton, B. L. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00540 · Cited by 47
Species differences in immune‐mediated CNS tissue injury and repair: A (neuro)inflammatory topic
Healy, L. M., Yaqubi, M., Ludwin, S. K., & Antel, J. P. (2019) · Glia · doi:10.1002/glia.23746 · Cited by 41
Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain
Azami Tameh, A., Clarner, T., Beyer, C., Atlasi, M. A., Hassanzadeh, G., & Naderian, H. (2013) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2013.03.004 · Cited by 43
Remyelination assessment by MRI texture analysis in a cuprizone mouse model
Yu, O., Steibel, J., Mauss, Y., Guignard, B., Eclancher, B., Chambron, J., & Grucker, D. (2004) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2004.08.017 · Cited by 43
Pathogenesis of Multiple Sclerosis: What Can We Learn from the Cuprizone Model
Acs, P., & Kalman, B. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-60761-720-4_20 · Cited by 42
Zha, Z., Liu, S., Liu, Y., Li, C., & Wang, L. (2022) · Antioxidants · doi:10.3390/antiox11081495 · Cited by 44
Hashimoto, M., Yamamoto, S., Iwasa, K., Yamashina, K., Ishikawa, M., Maruyama, K., Bosetti, F., & Yoshikawa, K. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.09.007 · Cited by 41
Wang, P., Gorter, R. P., de Jonge, J. C., Nazmuddin, M., Zhao, C., Amor, S., Hoekstra, D., & Baron, W. (2018) · Glia · doi:10.1002/glia.23328 · Cited by 40
Age Influences Microglial Activation After Cuprizone-Induced Demyelination
Klein, B., Mrowetz, H., Barker, C. M., Lange, S., Rivera, F. J., & Aigner, L. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00278 · Cited by 44
Probing demyelination and remyelination of the cuprizone mouse model using multimodality MRI
Wang, N., Zhuang, J., Wei, H., Dibb, R., Qi, Y. P., & Liu, C. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26758 · Cited by 41
Systemic TLR2 tolerance enhances central nervous system remyelination
Wasko, N. J., Kulak, M. J., Paul, D., Nicaise, A. M., Yeung, S. T., Nichols, F. C., Khanna, K. M., Crocker, S. J., Pachter, J. S., & Clark, R. B. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1540-2 · Cited by 42
Jia, Y., Zhang, D., Li, H., Luo, S., Xiao, Y., Li, H., Zhou, F., Wang, C., Feng, L., Wang, G., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114422 · Cited by 41
Haloperidol activates quiescent oligodendroglia precursor cells in the adult mouse brain
Wang, H., Xu, H., Niu, J., Mei, F., Li, X., Kong, J., Cai, W., & Xiao, L. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1068 · Cited by 42
Orije, J. E. M. J., Kara, F., Guglielmetti, C., Praet, J., der Linden, A. V., Ponsaerts, P., & Verhoye, M. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.04.012 · Cited by 42
Ye, J.-N., Chen, X.-S., Su, L., Liu, Y.-L., Cai, Q., Zhan, X.-L., Xu, Y., Zhao, S., & Yao, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054590 · Cited by 41
Presence and induction of the enzyme NAD(P)H: Quinone oxidoreductase 1 in the central nervous system
Stringer, J. L., Gaikwad, A., Gonzales, B. N., Long, D. J., Marks, L. M., & Jaiswal, A. K. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20048 · Cited by 41
Manto, M. U., & Marmolino, D. (2009) · The Cerebellum · doi:10.1007/s12311-009-0127-3 · Cited by 40
Strain differences in cuprizone induced demyelination
Yu, Q., Hui, R., Park, J., Huang, Y., Kusnecov, A. W., Dreyfus, C. F., & Zhou, R. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0181-3 · Cited by 40
Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination
das Neves, S. P., Delivanoglou, N., Ren, Y., Cucuzza, C. S., Makuch, M., Almeida, F., Sánchez, G., Barber, M. J., Rego, S., Schrader, R. M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.004 · Cited by 40
Cuprizone‐induced demyelination in CNP::GFP transgenic mice
Silvestroff, L., Bartucci, S., Soto, E., Gallo, V., Pasquini, J., & Franco, P. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22330 · Cited by 40
Serra-de-Oliveira, N., Boilesen, S. N., Carvalho, C. P. D. F., Sueur, L. D. P. L., Zollner, R. D. L., Spadari, R. C., Medalha, C. C., & de Castro, G. M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.038 · Cited by 41
Kuypers, N. J., Bankston, A. N., Howard, R. M., Beare, J. E., & Whittemore, S. R. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1240-15.2016 · Cited by 43
Lindner, M., Trebst, C., Heine, S., Skripuletz, T., Koutsoudaki, P. N., & Stangel, M. (2008) · Glia · doi:10.1002/glia.20682 · Cited by 41
Xu, H., Yang, H.-J., & Li, X. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0414-3 · Cited by 39
Icariin enhances remyelination process after acute demyelination induced by cuprizone exposure
Zhang, Y., Yin, L., Zheng, N., Zhang, L., Liu, J., Liang, W., & Wang, Q. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.01.025 · Cited by 39
Binamé, F., Pham-Van, L. D., Spenlé, C., Jolivel, V., Birmpili, D., Meyer, L. A. T., Jacob, L., Meyer, L., Mensah‐Nyagan, A. G., Po, C., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910378 · Cited by 39
Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment
Chen, Y., Kunjamma, R. B., Weiner, M., Chan, J. R., & Popko, B. (2021) · eLife · doi:10.7554/elife.65469 · Cited by 42
Werner, S. R., Saha, J. K., Broderick, C. L., Zhen, Y., Higgs, R. E., Duffin, K. L., & Smith, R. C. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9354-9 · Cited by 37
Napoli, E., Morin, D., Bernhardt, R., Buckpitt, A. R., & Cortopassi, G. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.04.001 · Cited by 39
Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis
Gharagozloo, M., Mace, J. W., & Calabresi, P. A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.995477 · Cited by 38
Polysialylation at Early Stages of Oligodendrocyte Differentiation Promotes Myelin Repair
Werneburg, S., Fuchs, H. L. S., Albers, I., Burkhardt, H., Gudi, V., Skripuletz, T., Stangel, M., Gerardy‐Schahn, R., & Hildebrandt, H. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1147-17.2017 · Cited by 38
The function of contactin‐2/TAG‐1 in oligodendrocytes in health and demyelinating pathology
Zoupi, L., Savvaki, M., Kalemaki, K., Kalafatakis, I., Sidiropoulou, K., & Karagogeos, D. (2017) · Glia · doi:10.1002/glia.23266 · Cited by 36
Kumar, P., Sharma, G., Gupta, V., Kaur, R., Thakur, K., Malik, R., Kumar, A., Kaushal, N., Katare, O. P., & Raza, K. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1296-0 · Cited by 38
Oligodendroglial Maturation Is Dependent on Intracellular Protein Shuttling
Göttle, P., Sabo, J. K., Heinen, A., Venables, G., Torres, K. J., Tzekova, N., Parras, C. M., Kremer, D., Hartung, H., Cate, H. S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1423-14.2015 · Cited by 37
Trebst, C., Heine, S., Lienenklaus, S., Lindner, M., Baumgärtner, W., Weiss, S., & Stangel, M. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0300-z · Cited by 38
How to Use the Cuprizone Model to Study De- and Remyelination
Kipp, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031445 · Cited by 37
“The figure is adapted from [32,33].”
Moll, N. M., Hong, E., Fauveau, M., Naruse, M., Kerninon, C., Tepavčević, V., Klopstein, A., Seilhean, D., Chew, L., Gallo, V., et al. (2013) · Glia · doi:10.1002/glia.22547 · Cited by 40
Siebert, J. R., Eade, A. M., & Osterhout, D. J. (2015) · BioMed Research International · doi:10.1155/2015/752572 · Cited by 40
Mechanisms of remyelination: recent insight from experimental models
Tanaka, T., & Yoshida, S. (2014) · BioMolecular Concepts · doi:10.1515/bmc-2014-0015 · Cited by 37
Parenti, R., Cicirata, F., Zappalà, A., Catania, A., D'Elia, F., Cicirata, V., Tress, O., & Willecke, K. (2010) · Glia · doi:10.1002/glia.21032 · Cited by 37
Caprariello, A. V., Batt, C. E., Zippe, I., Romito‐DiGiacomo, R. R., Karl, M. T., & Miller, R. H. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1706-15.2015 · Cited by 41
Smith, B. M., Giddens, M. M., Neil, J. E., Owino, S., Nguyen, T. T., Duong, D. M., Li, F., & Hall, R. A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.06.006 · Cited by 40
Inhibition of neutral sphingomyelinase 2 promotes remyelination
Yoo, S.-W., Agarwal, A., Smith, M. D., Khuder, S. S., Baxi, E. G., Thomas, A. G., Rojas, C. J., Moniruzzman, M., Slusher, B. S., Bergles, D. E., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba5210 · Cited by 38
Koutsoudaki, P. N., Hildebrandt, H., Gudi, V., Skripuletz, T., Škuljec, J., & Stangel, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.070 · Cited by 37
ADAM12 is expressed by astrocytes during experimental demyelination
Baertling, F., Kokozidou, M., Pufe, T., Clarner, T., Windoffer, R., Wruck, C. J., Brandenburg, L., Beyer, C., & Kipp, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.049 · Cited by 36
Remyelination After Cuprizone-Induced Demyelination Is Accelerated in Juvenile Mice
Pfeifenbring, S., Nessler, S., Wegner, C., Stadelmann, C., & Brück, W. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000214 · Cited by 39
Kumar, P., Sharma, G., Gupta, V., Kaur, R., Thakur, K., Malik, R., Kumar, A., Kaushal, N., & Raza, K. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00519 · Cited by 36
Soustelle, L., Antal, M. C., Lamy, J., Rousseau, F., Armspach, J., & de Sousa, P. L. (2019) · NMR in Biomedicine · doi:10.1002/nbm.4116 · Cited by 36
Pamphlett, R., Mak, R., Lee, J., Buckland, M. E., Harding, A. J., Jew, S. K., Paterson, D. J., Jones, M. W., & Lay, P. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233300 · Cited by 36
Yamazaki, R., Ohno, N., & Huang, J. K. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15142 · Cited by 36
New therapeutic avenues of MCSF for brain diseases and injuries
Pons, V., & Rivest, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00499 · Cited by 35
Sen, M. K., Almuslehi, M. S. M., Gyengesi, E., Myers, S. J., Shortland, P. J., Mahns, D. A., & Coorssen, J. R. (2019) · Cells · doi:10.3390/cells8111314 · Cited by 35
Metadata
- Authors
- Matsushima, G. K., & Morell, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Matsushima, Glenn K.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 11
- Issue
- 1
- Pages
- 107-116
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC8098267
- OpenAlex
- W2100904149
- Cited by
- 984
- References
- 45
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 42 · 2023: 50 · 2022: 58 · 2021: 48 · 2020: 55 · 2019: 75 · 2018: 59 · 2017: 65 · 2016: 39 · 2015: 58 · 2014: 39 · 2013: 53 · 2012: 40
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns011615-29, 5r01ns037815-05, 5r29ns035372-05)
- National Institute of Neurological Disorders and Stroke (NS37815, NS-11615, NS-35372)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cuprizone, demyelination, remyelination, oligodendrocyte apoptosis, microglia, myelin phagocytosis, oligodendrocyte precursor cells, myelin gene expression, C57BL/6 mice, copper chelators
- MeSH terms
- Animals, Central Nervous System, Chelating Agents, Cuprizone, Demyelinating Diseases, Mice, Inbred C57BL, Myelin Sheath, Oligodendroglia, Microglia, Models, Animal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
